GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
37.61
-0.33 (-0.87%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close37.94
Open37.58
Bid37.25 x 29200
Ask37.64 x 40000
Day's Range37.40 - 37.67
52 Week Range34.89 - 42.36
Volume4,222,633
Avg. Volume3,034,378
Market Cap90.841B
Beta (3Y Monthly)0.33
PE Ratio (TTM)37.91
EPS (TTM)0.99
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.96 (5.26%)
Ex-Dividend Date2018-11-15
1y Target Est42.87
Trade prices are not sourced from all markets
  • Cramer's lightning round: There are better drug stocks to...
    CNBC Videos7 days ago

    Cramer's lightning round: There are better drug stocks to...

    Jim Cramer flies through his responses to callers' stock questions, including one about the prospects for a drugmaker's stock.

  • Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
    American City Business Journalsyesterday

    Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay

    Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.

  • What’s the Market Opportunity for Zejula?
    Market Realist2 days ago

    What’s the Market Opportunity for Zejula?

    How Is Tesaro Positioned in December? As per GlaxoSmithKline’s (GSK) analyst call transcript, Tesaro’s (TSRO) Zejula is competing with AstraZeneca’s (AZN) Lynparza and Clovis Oncology’s (CLVS) Rubraca as maintenance therapy in the second-line platinum-sensitive ovarian cancer indication. GlaxoSmithKline (GSK) has estimated the annual incidence of these patients in the US market to be around 5,000.

  • Big Pharma Grants License to Kill Drug Programs as Costs Surge
    Bloomberg2 days ago

    Big Pharma Grants License to Kill Drug Programs as Costs Surge

    Industry executives long trained to sniff out blockbuster drugs are now having to hone another skill: a feel for medicines that are unsafe, unoriginal or just unlikely to succeed. As costs escalate, knowing when to terminate those medicines has become just as important as when to move forward. At AstraZeneca Plc, research boss Mene Pangalos figures he shut down about half the projects in the pipeline after joining eight years ago.

  • 3 Dividend Stocks That Pay You More Than Exxon Does
    Motley Fool3 days ago

    3 Dividend Stocks That Pay You More Than Exxon Does

    Looking for big yield? ExxonMobil has it, but these three stocks should also be on your radar.

  • Benzinga4 days ago

    Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

    Clovis Oncology Inc (NASDAQ: CLVS ) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK )'s proposed acquisition of TESARO Inc (NASDAQ: TSRO ), according to Gabelli Research. ...

  • How Tesaro Stock Performed in December
    Market Realist4 days ago

    How Tesaro Stock Performed in December

    How Is Tesaro Positioned in December? On December 7, Tesaro (TSRO) closed at $73.95, which is 0.23% higher than its previous closing price. The company rose 45.48% from $31.88 on November 1 to $46.38 on November 30. Tesaro has risen 59.44% between November 30 and December 7.

  • Is GlaxoSmithKline plc (GSK) A Good Stock To Buy?
    Insider Monkey4 days ago

    Is GlaxoSmithKline plc (GSK) A Good Stock To Buy?

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors’ favor when it comes to beating the market, […]

  • Here's Why Tesaro Rose 60.6% in November -- and Another 60% Since
    Motley Fool5 days ago

    Here's Why Tesaro Rose 60.6% in November -- and Another 60% Since

    Rumors of an acquisition swirled last month before being proven as fact in December.

  • Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?
    Insider Monkey6 days ago

    Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • Could These Be the Next 2 Biotech Buyouts?
    Motley Fool6 days ago

    Could These Be the Next 2 Biotech Buyouts?

    If GlaxoSmithKline's recent splurge signals a new round of acquisitions, these stocks could be next.

  • CNBC7 days ago

    Cramer's lightning round: There are better drug stocks to own than GlaxoSmithKline

    Jim Cramer flies through his responses to callers' stock questions, including one about the prospects for a drugmaker's stock.

  • Financial Times8 days ago

    [$$] GSK’s doses of corporate action this week bring no cure

    Is there another big UK company that has been half as disappointing as GlaxoSmithKline ? A business that once led the world in finding and developing pharmaceuticals is today reduced to expensive purchases ...

  • Gilead's (GILD) Harvoni and Descovy Get Approval in China
    Zacks10 days ago

    Gilead's (GILD) Harvoni and Descovy Get Approval in China

    Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.

  • This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger
    American City Business Journals10 days ago

    This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger

    OncoMed's clinical trial failures prevented the Redwood City company from achieving the financial promise of deals with Celgene, Bayer and GlaxoSmithKline. Now a London company is reverse merging with it to get its NASDAQ listing and Peninsula facility.

  • MarketWatch10 days ago

    GlaxoSmithKline's credit rating revised to negative at Moody's after Tesaro buyout deal

    The outlook on GlaxoSmithKline PLC's credit rating was revised to negative from stable at Moody's Investors Service, which cited the drug giant's proposed acquisition of Tesaro Inc. . Moody's affirmed Glaxo's A2 long-term credit rating and its Prime-1 short-term rating. "We have changed [Glaxo's] outlook to negative as the company will deleverage more slowly than expected following the acquisition of Tesaro," said Moody's analyst Knut Slatten. "While the acquisition allows for a solid strengthening of [Glaxo's] oncology franchise, we expect credit metrics to remain weak for a prolonged period of time." Glaxo announced Monday an agreement to buy Tesaro in a cash deal valued at $5.1 billion, including debt. Glaxo's stock has gained 8.1% year to date through Tuesday, while the SPDR Health Care Select Sector ETF has rallied 12.8% and the S&P 500 has edged up 1.0%.

  • Moody's10 days ago

    GlaxoSmithKline Capital Inc. -- Moody's changes GSK's outlook to negative; affirms A2 ratings

    Moody's Investors Service has today changed to negative from stable the outlook of GlaxoSmithKline plc (GSK) and its guaranteed subsidiaries. The change in outlook follows the company's 3 December announcement of its intention to acquire Tesaro for $5.1 billion. At the same time, Moody's has affirmed GSK's A2/(P)A2 long-term and (P)Prime-1 ratings.

  • Financial Times10 days ago

    [$$] Stocks to watch: Thomas Cook, GlaxoSmithKline, Electrolux, Capita

    hit a one-year high after interim results from the transport group proved better than feared, thanks largely to its rapidly shrinking rail division. A continued improvement of Stagecoach’s regional bus business helped bolster investor confidence, as did news that management was considering a full or partial sale of its US division. Exiting the US at the current net asset value would more than halve Stagecoach’s group debt, said RBC.

  • Financial Times10 days ago

    [$$] The London Report: Thomas Cook stocks reach sunnier climes

    The package holiday operator had halved over the previous six sessions on fears that it may be forced to launch an emergency rights issue. Analysts at Numis and Jefferies also concluded that Thomas Cook had enough liquidity to trade through the winter season. Jefferies, repeating “buy” advice, said Thomas Cook’s debt covenants had plenty of flexibility to cover the first half of 2019 and a sale of its airline stake had the potential to raise around £1.1bn.

  • GlaxoSmithKline (GSK) Stock Moves -0.7%: What You Should Know
    Zacks10 days ago

    GlaxoSmithKline (GSK) Stock Moves -0.7%: What You Should Know

    In the latest trading session, GlaxoSmithKline (GSK) closed at $38.34, marking a -0.7% move from the previous day.

  • Gilead (GILD) Announces Data on CAR T Therapy Candidate
    Zacks11 days ago

    Gilead (GILD) Announces Data on CAR T Therapy Candidate

    Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.

  • Benzinga11 days ago

    Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal

    GlaxoSmithKline plc (NYSE: GSK ) on Monday announced a $5.1 billion deal to acquire Tesaro Inc (NASDAQ: TSRO ) in a bid to augment its oncology franchise. The Analyst Wedbush analyst David Nierengarten ...

  • Company News For Dec 4, 2018
    Zacks11 days ago

    Company News For Dec 4, 2018

    Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT

  • Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%
    Zacks11 days ago

    Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%

    Glaxo (GSK) announces definitive deal to buy TESARO.